Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWR NYSE:RDY NASDAQ:SMMT NASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$85.60-1.4%$77.94$15.01▼$95.49$12.06B1.263.16 million shs1.83 million shsRDYDr. Reddy's Laboratories$11.78-0.2%$13.49$11.36▼$15.67$9.84B0.252.98 million shs3.23 million shsSMMTSummit Therapeutics$13.66-8.8%$15.03$12.55▼$30.98$10.60B-1.263.53 million shs8.15 million shsVERAVera Therapeutics$35.45-2.5%$37.00$19.07▼$56.05$2.54B0.922.53 million shs786,120 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals0.00%+15.21%+7.99%+15.82%+437.69%RDYDr. Reddy's Laboratories0.00%-6.81%-22.77%-13.86%-19.60%SMMTSummit Therapeutics0.00%-1.09%-3.67%-38.13%-51.23%VERAVera Therapeutics0.00%-7.92%-12.47%-5.94%+56.65%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$85.60-1.4%$77.94$15.01▼$95.49$12.06B1.263.16 million shs1.83 million shsRDYDr. Reddy's Laboratories$11.78-0.2%$13.49$11.36▼$15.67$9.84B0.252.98 million shs3.23 million shsSMMTSummit Therapeutics$13.66-8.8%$15.03$12.55▼$30.98$10.60B-1.263.53 million shs8.15 million shsVERAVera Therapeutics$35.45-2.5%$37.00$19.07▼$56.05$2.54B0.922.53 million shs786,120 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals0.00%+15.21%+7.99%+15.82%+437.69%RDYDr. Reddy's Laboratories0.00%-6.81%-22.77%-13.86%-19.60%SMMTSummit Therapeutics0.00%-1.09%-3.67%-38.13%-51.23%VERAVera Therapeutics0.00%-7.92%-12.47%-5.94%+56.65%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 2.71Moderate Buy$93.839.62% UpsideRDYDr. Reddy's Laboratories 1.67ReduceN/AN/ASMMTSummit Therapeutics 2.44Hold$26.1591.47% UpsideVERAVera Therapeutics 2.77Moderate Buy$84.58138.60% UpsideCurrent Analyst Ratings BreakdownLatest VERA, SMMT, RDY, and ARWR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2026SMMTSummit Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$15.007/24/2026SMMTSummit Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$45.00 ➝ $38.007/24/2026SMMTSummit Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$40.00 ➝ $38.007/24/2026SMMTSummit Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight7/23/2026RDYDr. Reddy's Laboratories Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)7/23/2026ARWRArrowhead Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$100.00 ➝ $120.007/23/2026ARWRArrowhead Pharmaceuticals Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$110.00 ➝ $126.007/23/2026SMMTSummit Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral7/22/2026ARWRArrowhead Pharmaceuticals Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$90.00 ➝ $115.007/17/2026SMMTSummit Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026VERAVera Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$829.45M14.54$0.12 per share716.92$3.64 per share23.52RDYDr. Reddy's Laboratories$3.58B2.75$0.85 per share13.92$4.90 per share2.40SMMTSummit TherapeuticsN/AN/AN/AN/A$0.85 per shareN/AVERAVera TherapeuticsN/AN/AN/AN/A$8.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$1.63M-$2.15N/AN/AN/A-48.38%-55.09%-18.13%8/4/2026 (Estimated)RDYDr. Reddy's Laboratories$456M$0.4426.7618.992.1710.15%9.49%6.32%N/ASMMTSummit Therapeutics-$1.08B-$1.12N/AN/AN/AN/A-183.84%-154.65%N/AVERAVera Therapeutics-$299.61M-$5.54N/AN/AN/AN/A-74.86%-60.18%8/4/2026 (Estimated)Latest VERA, SMMT, RDY, and ARWR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026Q3 2026ARWRArrowhead Pharmaceuticals-$1.2767N/AN/AN/A$44.17 millionN/A8/4/2026Q2 2026VERAVera Therapeutics-$1.60N/AN/AN/A$1.28 millionN/A7/23/2026Q2 2026SMMTSummit Therapeutics-$0.2744-$0.28-$0.0056-$0.28$0.11 millionN/A7/21/2026Q1 26/27RDYDr. Reddy's Laboratories$0.0918$0.06-$0.0318$0.06$850.56 million$850.26 million5/12/2026Q4 25/26RDYDr. Reddy's Laboratories$0.09$0.06-$0.03-$0.03$886.58 million$852.55 million5/7/2026Q2 2026ARWRArrowhead Pharmaceuticals-$1.0950-$0.93+$0.1650-$0.93$73.84 million$73.74 million5/7/2026Q1 2026VERAVera Therapeutics-$1.3284-$1.69-$0.3616-$1.69$0.43 millionN/A5/1/2026Q1 2026SMMTSummit Therapeutics-$0.2692-$0.24+$0.0292-$0.24$0.05 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories$0.060.51%+6.96%13.64%N/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals1.416.236.23RDYDr. Reddy's Laboratories0.031.901.34SMMTSummit TherapeuticsN/A7.417.41VERAVera Therapeutics0.1513.6413.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%RDYDr. Reddy's Laboratories3.85%SMMTSummit Therapeutics4.61%VERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals3.60%RDYDr. Reddy's Laboratories2.00%SMMTSummit Therapeutics83.50%VERAVera Therapeutics15.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400140.86 million135.79 millionOptionableRDYDr. Reddy's Laboratories27,527834.67 million817.97 millionOptionableSMMTSummit Therapeutics110776.16 million128.07 millionOptionableVERAVera Therapeutics4071.78 million60.37 millionOptionableVERA, SMMT, RDY, and ARWR HeadlinesRecent News About These CompaniesVera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJuly 25 at 2:28 AM | americanbankingnews.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of "Moderate Buy" by BrokeragesJuly 25 at 2:28 AM | marketbeat.comFifth Third Bancorp Purchases Shares of 35,492 Vera Therapeutics, Inc. $VERAJuly 24 at 3:43 AM | marketbeat.comJ. Safra Sarasin Holding AG Has $524,000 Stake in Vera Therapeutics, Inc. $VERAJuly 16, 2026 | marketbeat.comVera Therapeutics Inc - Ordinary Shares - Class AJuly 13, 2026 | money.usnews.comAnalysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA), Crinetics Pharmaceuticals (CRNX) and Revolution Medicines (RVMD)July 12, 2026 | theglobeandmail.comCandriam S.C.A. Increases Position in Vera Therapeutics, Inc. $VERAJuly 12, 2026 | marketbeat.comVera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets LaunchJuly 11, 2026 | marketbeat.comVera Therapeutics (VERA) Stock Looks Fully Valued After Its 185% RunJuly 10, 2026 | finance.yahoo.comVera Therapeutics (VERA) Could Be 92% Below Fair Value After FDA ApprovalJuly 10, 2026 | finance.yahoo.comVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 10, 2026 | globenewswire.comVera Therapeutics (NASDAQ:VERA) Stock Price Down 6.8% on Insider SellingJuly 10, 2026 | marketbeat.comQ3 EPS Forecast for Vera Therapeutics Decreased by AnalystJuly 10, 2026 | marketbeat.comMarshall Fordyce Sells 46,250 Shares of Vera Therapeutics (NASDAQ:VERA) StockJuly 10, 2026 | insidertrades.comVera Therapeutics: A Crowded IgAN Market Leaves No Room For A Premium (Downgrade)July 9, 2026 | seekingalpha.comVera Therapeutics (NASDAQ:VERA) CEO Sells $1,956,375.00 in StockJuly 9, 2026 | marketbeat.comVera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William TurnerJuly 9, 2026 | globenewswire.comVera Therapeutics wins FDA nod for closely watched kidney disease drugJuly 8, 2026 | finance.yahoo.comPharmalittle: We’re reading about a Vera kidney drug approval, a U.K. Enhertu pricing deal, and moreJuly 8, 2026 | statnews.comSFDA grants accelerated approval to Vera Therapeutics' TrutaknaJuly 8, 2026 | finance.yahoo.comWedbush Issues Positive Forecast for Vera Therapeutics (NASDAQ:VERA) Stock PriceJuly 8, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesRocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 2026Rocket Lab's NASA Win Tests Key Support After Sharp PullbackBy Ryan Hasson | June 26, 2026Costco’s Secret Growth Engine May Be Running Out of GasBy Dan Schmidt | June 28, 2026AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space SectorBy Jessica Mitacek | July 17, 2026The Bond Market Just Sent Amazon a Message Investors Shouldn’t IgnoreBy Sam Quirke | July 14, 2026VERA, SMMT, RDY, and ARWR Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$85.60 -1.18 (-1.36%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$86.25 +0.65 (+0.76%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Dr. Reddy's Laboratories NYSE:RDY$11.78 -0.03 (-0.21%) Closing price 07/24/2026 03:59 PM EasternExtended Trading$11.80 +0.03 (+0.25%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.Summit Therapeutics NASDAQ:SMMT$13.66 -1.32 (-8.81%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$13.72 +0.06 (+0.48%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.Vera Therapeutics NASDAQ:VERA$35.45 -0.90 (-2.48%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$35.50 +0.05 (+0.14%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
